UroGen Pharma (URGN) Gains from Investment Securities (2017)
UroGen Pharma's (URGN) quarterly Gains from Investment Securities came in at $277000.0 in Q2 2017, up 354.13% on a QoQ basis from -$109000.0 in Q1 2017.
Powered by 
Analysis
UroGen Pharma (URGN) Gains from Investment Securities (2017) Analysis & Trends
UroGen Pharma (URGN) has 1 years of Gains from Investment Securities data on file, last reported at $277000.0 in Q2 2017.
- Quarterly Gains from Investment Securities changed N/A year-over-year to $277000.0 in Q2 2017, while the trailing twelve-month figure through Dec 2017 was $168000.0 (changed N/A YoY) and the FY2017 annual result came in at $168000.0, down 93.87% from the prior year.
- Gains from Investment Securities rose to $277000.0 in Q2 2017, from -$109000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $277000.0 in Q2 2017 to a low of -$109000.0 in Q1 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | UroGen Pharma | 2.23 Bn | 2.12 Bn | 65.88 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2017 | 277,000.00 |
| Mar 31, 2017 | -109,000.00 |